GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » ROE %

CARsgen Therapeutics Holdings (HKSE:02171) ROE % : -69.60% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CARsgen Therapeutics Holdings's annualized net income for the quarter that ended in Dec. 2024 was HK$-953.59 Mil. CARsgen Therapeutics Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2024 was HK$1,370.07 Mil. Therefore, CARsgen Therapeutics Holdings's annualized ROE % for the quarter that ended in Dec. 2024 was -69.60%.

The historical rank and industry rank for CARsgen Therapeutics Holdings's ROE % or its related term are showing as below:

HKSE:02171' s ROE % Range Over the Past 10 Years
Min: -690.62   Med: -44.79   Max: -30.99
Current: -54.47

During the past 6 years, CARsgen Therapeutics Holdings's highest ROE % was -30.99%. The lowest was -690.62%. And the median was -44.79%.

HKSE:02171's ROE % is ranked worse than
59.51% of 1304 companies
in the Biotechnology industry
Industry Median: -42.01 vs HKSE:02171: -54.47

CARsgen Therapeutics Holdings ROE % Historical Data

The historical data trend for CARsgen Therapeutics Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings ROE % Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE %
Get a 7-Day Free Trial - -690.62 -30.99 -34.57 -55.00

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -38.20 -34.20 -34.27 -42.26 -69.60

Competitive Comparison of CARsgen Therapeutics Holdings's ROE %

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's ROE % falls into.


;
;

CARsgen Therapeutics Holdings ROE % Calculation

CARsgen Therapeutics Holdings's annualized ROE % for the fiscal year that ended in Dec. 2024 is calculated as

ROE %=Net Income (A: Dec. 2024 )/( (Total Stockholders Equity (A: Dec. 2023 )+Total Stockholders Equity (A: Dec. 2024 ))/ count )
=-852.143/( (1970.661+1128.217)/ 2 )
=-852.143/1549.439
=-55.00 %

CARsgen Therapeutics Holdings's annualized ROE % for the quarter that ended in Dec. 2024 is calculated as

ROE %=Net Income (Q: Dec. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Dec. 2024 ))/ count )
=-953.59/( (1611.925+1128.217)/ 2 )
=-953.59/1370.071
=-69.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2024) net income data. ROE % is displayed in the 30-year financial page.


CARsgen Therapeutics Holdings  (HKSE:02171) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-953.59/1370.071
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-953.59 / 70.648)*(70.648 / 2024.8405)*(2024.8405 / 1370.071)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1349.78 %*0.0349*1.4779
=ROA %*Equity Multiplier
=-47.11 %*1.4779
=-69.60 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-953.59/1370.071
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-953.59 / -952.85) * (-952.85 / -524.524) * (-524.524 / 70.648) * (70.648 / 2024.8405) * (2024.8405 / 1370.071)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0008 * 1.8166 * -742.45 % * 0.0349 * 1.4779
=-69.60 %

Note: The net income data used here is two times the semi-annual (Dec. 2024) net income data. The Revenue data used here is two times the semi-annual (Dec. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


CARsgen Therapeutics Holdings ROE % Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Bei Jing Shen Nong Tou Zi Guan Li Gu Fen You Xian Gong Si 2102 Investment manager
Candock Holdings Limited 2501 Other
Yi Jie Sheng Wu Ji Shu Kong Gu You Xian Gong Si 2501 Other
Yi De Kong Gu You Xian Gong Si 2501 Other
Quan Zhou Shi Ding Wo Chuang Feng Tou Zi Zhong Xin You Xian He Huo 2501 Other
Yang Xuehong 2501 Other
Wang Huamao 2401 A concert party to an agreement to buy shares
Li Zonghai 2401 A concert party to an agreement to buy shares
Guo Bingsen 2401 A concert party to an agreement to buy shares
Accure Biotech Limited 2501 Other
Cart Biotech Limited 2501 Other
Chen Haiou 2501 Other
Guo Xiaojing 2501 Other
He Xi Holdings Limited 2501 Other
Redelle Holding Limited 2501 Other

CARsgen Therapeutics Holdings Headlines

No Headlines